Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33638308,elimination constant kel,BNN27 was found to have an elimination constant kel = 0.465 h-1 and mean residence time (MRT) 2.154 h in the mouse serum.,"Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638308/),1/[h],0.465,2903,DB01708,Dehydroepiandrosterone
,33638308,mean residence time (MRT),BNN27 was found to have an elimination constant kel = 0.465 h-1 and mean residence time (MRT) 2.154 h in the mouse serum.,"Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638308/),h,2.154,2904,DB01708,Dehydroepiandrosterone
,33638308,t C max,The maximum concentration (Cmax ) in the retina was detected at 2 h ( t C max ) after intraperitoneal administration and was equal to 1100 ng/g.,"Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638308/),h,2,2905,DB01708,Dehydroepiandrosterone
,33638308,t C max,The maximum concentration (Cmax ) in the retina was detected at 2 h ( t C max ) after intraperitoneal administration and was equal to 1100 ng/g.,"Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638308/),[ng] / [g],1100,2906,DB01708,Dehydroepiandrosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],0.82,5456,DB01708,Dehydroepiandrosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.48,5457,DB01708,Dehydroepiandrosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.31,5458,DB01708,Dehydroepiandrosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],0.88,5459,DB01708,Dehydroepiandrosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.8,5460,DB01708,Dehydroepiandrosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.4,5461,DB01708,Dehydroepiandrosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.0,5462,DB01708,Dehydroepiandrosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],10.7,5463,DB01708,Dehydroepiandrosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.8,5464,DB01708,Dehydroepiandrosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.4,5465,DB01708,Dehydroepiandrosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.0,5466,DB01708,Dehydroepiandrosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],10.7,5467,DB01708,Dehydroepiandrosterone
,12236849,first-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.17,5468,DB01708,Dehydroepiandrosterone
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.17,5469,DB01708,Dehydroepiandrosterone
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.16,5470,DB01708,Dehydroepiandrosterone
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.10,5471,DB01708,Dehydroepiandrosterone
,12236849,IC50s,"In the multiple-dose study, IC50s were 1.74 and 1.49 micro g ml(-1) for the 12.5 and 25 mg doses, respectively.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.74,5472,DB01708,Dehydroepiandrosterone
,12236849,IC50s,"In the multiple-dose study, IC50s were 1.74 and 1.49 micro g ml(-1) for the 12.5 and 25 mg doses, respectively.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.49,5473,DB01708,Dehydroepiandrosterone
,14595703,K(m),"In renal cortical slice experiments, uptake of indoxyl sulphate was a saturable process with a K(m) of 43.0 microm.",Pharmacokinetics and tissue distribution of uraemic indoxyl sulphate in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595703/),μm,43.0,20533,DB01708,Dehydroepiandrosterone
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],13.76,36625,DB01708,Dehydroepiandrosterone
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],4.77,36626,DB01708,Dehydroepiandrosterone
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],190,36627,DB01708,Dehydroepiandrosterone
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],96.75,36628,DB01708,Dehydroepiandrosterone
,11765025,Peak levels,Peak levels of testosterone total conjugates in urine (range 300-6000 microg/L) were attained a few hours after dosing.,Human nutritional supplements in the horse. Dehydroepiandrosterone versus androstenedione: comparative effects on the androgen profile and consequences for doping analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765025/),[μg] / [l],300-6000,39351,DB01708,Dehydroepiandrosterone
,14603503,time to reach maximum concentration (t(max)),"Moreover, the time to reach maximum concentration (t(max)) decreased from 2.2 with the untreated drug to 0.5 h with the coground product, and the mean permanence time of DHEA within physiological levels was four times longer for the coground product compared with the untreated drug.",Enhancement of dehydroepiandrosterone solubility and bioavailability by ternary complexation with alpha-cyclodextrin and glycine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603503/),h,2.2,57241,DB01708,Dehydroepiandrosterone
,14603503,time to reach maximum concentration (t(max)),"Moreover, the time to reach maximum concentration (t(max)) decreased from 2.2 with the untreated drug to 0.5 h with the coground product, and the mean permanence time of DHEA within physiological levels was four times longer for the coground product compared with the untreated drug.",Enhancement of dehydroepiandrosterone solubility and bioavailability by ternary complexation with alpha-cyclodextrin and glycine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603503/),h,0.5,57242,DB01708,Dehydroepiandrosterone
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],11,61031,DB01708,Dehydroepiandrosterone
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],49,61032,DB01708,Dehydroepiandrosterone
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,35,61033,DB01708,Dehydroepiandrosterone
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,78,61034,DB01708,Dehydroepiandrosterone
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,58,61035,DB01708,Dehydroepiandrosterone
,1533090,peak steroid concentrations,"Mean peak steroid concentrations after 150 mg (300 mg) doses were dehydroepiandrosterone 1617 (2639) ng/dl, 7 (11.5)-fold above placebo; dehydroepiandrosterone S 1185 (1688) micrograms/dl, 14 (20)-fold above placebo; and testosterone 183 (311) ng/dl, 4 (7)-fold above placebo.",Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1533090/),[ng] / [dl],1617,66084,DB01708,Dehydroepiandrosterone
,1533090,peak steroid concentrations,"Mean peak steroid concentrations after 150 mg (300 mg) doses were dehydroepiandrosterone 1617 (2639) ng/dl, 7 (11.5)-fold above placebo; dehydroepiandrosterone S 1185 (1688) micrograms/dl, 14 (20)-fold above placebo; and testosterone 183 (311) ng/dl, 4 (7)-fold above placebo.",Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1533090/),[μg] / [dl],1185,66085,DB01708,Dehydroepiandrosterone
,1533090,peak steroid concentrations,"Mean peak steroid concentrations after 150 mg (300 mg) doses were dehydroepiandrosterone 1617 (2639) ng/dl, 7 (11.5)-fold above placebo; dehydroepiandrosterone S 1185 (1688) micrograms/dl, 14 (20)-fold above placebo; and testosterone 183 (311) ng/dl, 4 (7)-fold above placebo.",Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1533090/),[ng] / [dl],183,66086,DB01708,Dehydroepiandrosterone
,25556680,time to PSA progression,"Median time to PSA progression and radiographic disease progression was 6.7 and 12.9 months, respectively.","Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556680/),month,6.7,72965,DB01708,Dehydroepiandrosterone
,10707113,Vss,Male control rats cleared prednisolone faster [3.68 +/- 1.30 (males) vs 1.01 +/- 0.7 l/h/kg; p < 0.05] and had larger Vss (1.38 +/- 0.459 vs 0.394 +/- 0.500 l/kg; p < 0.05) than females both due largely to lesser plasma protein binding.,Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707113/),[l] / [kg],1.38,78561,DB01708,Dehydroepiandrosterone
,10707113,Vss,Male control rats cleared prednisolone faster [3.68 +/- 1.30 (males) vs 1.01 +/- 0.7 l/h/kg; p < 0.05] and had larger Vss (1.38 +/- 0.459 vs 0.394 +/- 0.500 l/kg; p < 0.05) than females both due largely to lesser plasma protein binding.,Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707113/),[l] / [kg],0.394,78562,DB01708,Dehydroepiandrosterone
,124325,metabolic clearance rate,The metabolic clearance rate of progesterone from blood was 3-13 plus or minus 0-35 (S.E.M.) 1/min in ten experiments on six goats; values tended to be slightly higher in pregnant than in non-pregnant goats.,"Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],3-13,86668,DB01708,Dehydroepiandrosterone
less,124325,production rate,"The production rate of progesterone at oestrus, and at day 3 of the normal cycle, was less than 0-01 mug/min.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-01,86669,DB01708,Dehydroepiandrosterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],8-5,86670,DB01708,Dehydroepiandrosterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],14-6,86671,DB01708,Dehydroepiandrosterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],15-3,86672,DB01708,Dehydroepiandrosterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-6,86673,DB01708,Dehydroepiandrosterone
,124325,clearance rate,"The mean clearance rate of progesterone by the udder was 0-279 1/min, 8-8% of the metabolic clearance rate.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],0-279,86674,DB01708,Dehydroepiandrosterone
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-64,86675,DB01708,Dehydroepiandrosterone
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[ng] / [g·min],0-11-1-88,86676,DB01708,Dehydroepiandrosterone
,9626121,area under the concentration-time curve (AUC) 0-12 h,"Oral administration of 50 mg DHEA led to restoration of DHEA(S) baseline levels, whereas 100 mg induced supraphysiological concentrations [baseline vs. 50 mg DHEA vs. 100 mg DHEA: area under the concentration-time curve (AUC) 0-12 h DHEA: 280 +/- 85 vs.",Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),,280,87582,DB01708,Dehydroepiandrosterone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],89.1,87583,DB01708,Dehydroepiandrosterone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],139.6,87584,DB01708,Dehydroepiandrosterone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],213.3,87585,DB01708,Dehydroepiandrosterone
more,10999810,apparent terminal half-life,"1) Blood DHEA had an apparent terminal half-life of more than 20 h, the same order of magnitude as that of blood DHEAS, a result explainable by back-hydrolysis of the large amount of DHEAS formed after oral administration of DHEA, a mechanism providing long-lived unconjugated DHEA and metabolites.",Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999810/),h,20,110446,DB01708,Dehydroepiandrosterone
,19836365,bioavailability,The oral formulation had a lower bioavailability (47%) compared to the sc formulation (84%).,"Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19836365/),%,47,130165,DB01708,Dehydroepiandrosterone
,19836365,bioavailability,The oral formulation had a lower bioavailability (47%) compared to the sc formulation (84%).,"Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19836365/),%,84,130166,DB01708,Dehydroepiandrosterone
,12970301,metabolic clearance rate,"After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),[l] / [d],99.9,138125,DB01708,Dehydroepiandrosterone
,12970301,terminal half-life,"After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),h,4.5,138126,DB01708,Dehydroepiandrosterone
,12970301,systemic availability,"Following a 50-mg DHEA PO dose, systemic availability was only 3.1 +/- 0.4%.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),%,3.1,138127,DB01708,Dehydroepiandrosterone
,6236000,metabolic clearance rates (MCR),The metabolic clearance rates (MCR) (means +/- SEM) for normal young men and women were 15.2 +/- 1.7 1/24 h (8.2 +/- 0.7 1/m2/24 h) and 11.8 +/- 0.8 1/24 h (7.3 +/- 0.4 1/m2/24 h) respectively.,Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6236000/),[1] / [24·h],15.2,158898,DB01708,Dehydroepiandrosterone
,6236000,metabolic clearance rates (MCR),The metabolic clearance rates (MCR) (means +/- SEM) for normal young men and women were 15.2 +/- 1.7 1/24 h (8.2 +/- 0.7 1/m2/24 h) and 11.8 +/- 0.8 1/24 h (7.3 +/- 0.4 1/m2/24 h) respectively.,Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6236000/),[1] / [24·h·m2],8.2,158899,DB01708,Dehydroepiandrosterone
,6236000,metabolic clearance rates (MCR),The metabolic clearance rates (MCR) (means +/- SEM) for normal young men and women were 15.2 +/- 1.7 1/24 h (8.2 +/- 0.7 1/m2/24 h) and 11.8 +/- 0.8 1/24 h (7.3 +/- 0.4 1/m2/24 h) respectively.,Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6236000/),[1] / [24·h],11.8,158900,DB01708,Dehydroepiandrosterone
,6236000,metabolic clearance rates (MCR),The metabolic clearance rates (MCR) (means +/- SEM) for normal young men and women were 15.2 +/- 1.7 1/24 h (8.2 +/- 0.7 1/m2/24 h) and 11.8 +/- 0.8 1/24 h (7.3 +/- 0.4 1/m2/24 h) respectively.,Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6236000/),[1] / [24·h·m2],7.3,158901,DB01708,Dehydroepiandrosterone
,6236000,blood production rates,Coupled with the plasma levels of 5.07 +/- 1.95 and 4.02 +/- 0.57 mumole/L the resulting blood production rates were 76.7 +/- 25.7 and 48.0 +/- 9.4 mumole/24 h for men and women respectively.,Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6236000/),[mumole] / [24·h],76.7,158902,DB01708,Dehydroepiandrosterone
,6236000,blood production rates,Coupled with the plasma levels of 5.07 +/- 1.95 and 4.02 +/- 0.57 mumole/L the resulting blood production rates were 76.7 +/- 25.7 and 48.0 +/- 9.4 mumole/24 h for men and women respectively.,Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6236000/),[mumole] / [24·h],48.0,158903,DB01708,Dehydroepiandrosterone
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],15.8,162229,DB01708,Dehydroepiandrosterone
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],16.3,162230,DB01708,Dehydroepiandrosterone
,11055323,time to peak plasma level,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.2,162231,DB01708,Dehydroepiandrosterone
,11055323,half life,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.17,162232,DB01708,Dehydroepiandrosterone
,11055323,apparent clearance,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[l] / [h],172,162233,DB01708,Dehydroepiandrosterone
,11055323,apparent mean volume of distribution,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),l,540,162234,DB01708,Dehydroepiandrosterone
,8789729,metabolic clearance rate,The mean +/- SE metabolic clearance rate of the intravenous DHA was 404 +/- 49 L/day.,Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),[l] / [d],404,163060,DB01708,Dehydroepiandrosterone
,8789729,metabolic clearance rate,"The mean metabolic clearance rate was 2,601 +/- 261 L/day after oral administration, and the calculated absorption was 16.3 +/- 2.5%.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),[l] / [d],"2,601",163061,DB01708,Dehydroepiandrosterone
,8789729,absorption,"The mean metabolic clearance rate was 2,601 +/- 261 L/day after oral administration, and the calculated absorption was 16.3 +/- 2.5%.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),%,16.3,163062,DB01708,Dehydroepiandrosterone
,8789729,conversion ratio,"DHA to DHAS, as the conversion ratio of the orally administered DHA measured in the blood as [4-14C]DHAS was 63.3 +/- 13.6, whereas the conversion ratio of intravenously administered DHA to DHAS was 9.3 +/- 2.0.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),,63.3,163063,DB01708,Dehydroepiandrosterone
,8789729,conversion ratio,"DHA to DHAS, as the conversion ratio of the orally administered DHA measured in the blood as [4-14C]DHAS was 63.3 +/- 13.6, whereas the conversion ratio of intravenously administered DHA to DHAS was 9.3 +/- 2.0.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),,9.3,163064,DB01708,Dehydroepiandrosterone
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],1.44,169553,DB01708,Dehydroepiandrosterone
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],0.82,169554,DB01708,Dehydroepiandrosterone
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],108.3,177886,DB01708,Dehydroepiandrosterone
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],43.4,177887,DB01708,Dehydroepiandrosterone
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],2.1,177888,DB01708,Dehydroepiandrosterone
,1403604,biliary excretion,The biliary excretion was 46% of the dose within 48 h and about half of the radioactive biliary excreta entered the enterohepatic circulation system.,The biological fate of sodium prasterone sulfate after vaginal administration. I. Absorption and excretion in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403604/),%,46,178130,DB01708,Dehydroepiandrosterone
,2761263,metabolic clearance,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[body·d·l·surface] / [area(m2],447,187721,DB01708,Dehydroepiandrosterone
,2761263,metabolic clearance,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[l] / [d·m2],346,187722,DB01708,Dehydroepiandrosterone
,2761263,production rates,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[mg] / [d·m2],2.21,187723,DB01708,Dehydroepiandrosterone
,2761263,production rates,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[mg] / [d·m2],1.70,187724,DB01708,Dehydroepiandrosterone
,17482394,signal-to-noise ratio,In 200 microl of plasma samples the limit of quantitation was as low as 0.025 microg/ml with a signal-to-noise ratio of 10.,Determination of a new active steroid by high performance liquid chromatography with laser-induced fluorescence detection following the pre-column derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482394/),,10,191875,DB01708,Dehydroepiandrosterone
,17482394,clearance for elimination,"Values for clearance for elimination, volume of distribution at steady state and terminal half life in the above case were determined as 50.3+/-1.1 ml/min kg, 1329.0+/-111.0 ml/kg and 44.0+/-2.7 min, respectively.",Determination of a new active steroid by high performance liquid chromatography with laser-induced fluorescence detection following the pre-column derivatization. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482394/),[ml] / [kg·min],50.3,191876,DB01708,Dehydroepiandrosterone
,17482394,volume of distribution at steady state,"Values for clearance for elimination, volume of distribution at steady state and terminal half life in the above case were determined as 50.3+/-1.1 ml/min kg, 1329.0+/-111.0 ml/kg and 44.0+/-2.7 min, respectively.",Determination of a new active steroid by high performance liquid chromatography with laser-induced fluorescence detection following the pre-column derivatization. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482394/),[ml] / [kg],1329.0,191877,DB01708,Dehydroepiandrosterone
,17482394,terminal half life,"Values for clearance for elimination, volume of distribution at steady state and terminal half life in the above case were determined as 50.3+/-1.1 ml/min kg, 1329.0+/-111.0 ml/kg and 44.0+/-2.7 min, respectively.",Determination of a new active steroid by high performance liquid chromatography with laser-induced fluorescence detection following the pre-column derivatization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482394/),min,44.0,191878,DB01708,Dehydroepiandrosterone
,27934638,liver tissue-to-plasma concentration ratio (Kpliver),"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),,41.8,198137,DB01708,Dehydroepiandrosterone
,27934638,liver tissue-to-plasma concentration ratio (Kpliver),"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),,5.07,198138,DB01708,Dehydroepiandrosterone
,27934638,distribution volume,"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),[ml] / [rat],247,198139,DB01708,Dehydroepiandrosterone
,27934638,distribution volume,"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),[ml] / [rat],59,198140,DB01708,Dehydroepiandrosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],27,207812,DB01708,Dehydroepiandrosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],221,207813,DB01708,Dehydroepiandrosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],343,207814,DB01708,Dehydroepiandrosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],414,207815,DB01708,Dehydroepiandrosterone
<,31814707,urinary excretion,The urinary excretion of AZD7594 was negligible (<0.02%).,"Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814707/),%,0.02,213620,DB01708,Dehydroepiandrosterone
,6444220,MCR,"When compared to the nonpregnancy state, term pregnancy was not associated with a change in plasma DHEA concentrations, but the MCR of DHEA of 76.8 +/- 18.8 (SE) liters/kg.day was 2.5-fold higher and the t1/2 of 22.5 +/- 3.6 min was 2-fold lower.","The use of constant infusion of unlabeled dehydroepiandrosterone for the assessment of its metabolic clearance rate, its half-life, and its conversion into estrogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6444220/),[l] / [d·kg],76.8,227412,DB01708,Dehydroepiandrosterone
,6444220,t1/2,"When compared to the nonpregnancy state, term pregnancy was not associated with a change in plasma DHEA concentrations, but the MCR of DHEA of 76.8 +/- 18.8 (SE) liters/kg.day was 2.5-fold higher and the t1/2 of 22.5 +/- 3.6 min was 2-fold lower.","The use of constant infusion of unlabeled dehydroepiandrosterone for the assessment of its metabolic clearance rate, its half-life, and its conversion into estrogens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6444220/),min,22.5,227413,DB01708,Dehydroepiandrosterone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,58,227698,DB01708,Dehydroepiandrosterone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,50,227699,DB01708,Dehydroepiandrosterone
,29590007,PFS,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),month,9,227700,DB01708,Dehydroepiandrosterone
,10372727,area under the curve (AUC) 0-12 h,"The intake of 50 mg DHEA led to an increase in serum DHEAS to mean levels of young adult men, whereas 100 mg DHEA induced supraphysiological concentrations [placebo vs. 50 mg DHEA vs. 100 mg DHEA; area under the curve (AUC) 0-12 h (mean +/- SD) for DHEA, 108 +/- 22 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,108,228141,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],33,228142,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],114,228143,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],164,228144,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,510,228145,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,635,228146,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],1443,228147,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],2537,228148,DB01708,Dehydroepiandrosterone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],3254,228149,DB01708,Dehydroepiandrosterone
,6444496,C,"Among these 15 women, C ranged from a low of 4.7 ml/min in a woman with severe pre-eclampsia to a high of 28.5 ml/min in a woman with twins.",Relationship of maternal placental blood flow to the placental clearance of maternal plasma dehydroisoandrosterone sulfate through placental estradiol formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6444496/),[ml] / [min],4.7,235020,DB01708,Dehydroepiandrosterone
,6444496,C,"Among these 15 women, C ranged from a low of 4.7 ml/min in a woman with severe pre-eclampsia to a high of 28.5 ml/min in a woman with twins.",Relationship of maternal placental blood flow to the placental clearance of maternal plasma dehydroisoandrosterone sulfate through placental estradiol formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6444496/),[ml] / [min],28.5,235021,DB01708,Dehydroepiandrosterone
,24771350,half-life (t1/2),"PK demonstrated a half-life (t1/2) ranging from 16 to 35 h, rapid absorption and dose proportionality.","Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771350/),h,16 to 35,237567,DB01708,Dehydroepiandrosterone
,31929946,flow rate,"After extraction from rat plasma by a simple protein-precipitation method, the analyte was separated on a C18 column (2.1 mm × 50 mm, 1.7 μm) using water with 0.1% formic acid and acetonitrile as the mobile phase delivered at a flow rate of 0.4 mL/min.","Pharmacokinetics and enterohepatic circulation of jervine, an antitumor steroidal alkaloid from Veratrum nigrum in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929946/),[ml] / [min],0.4,240888,DB01708,Dehydroepiandrosterone
,8943796,metabolic clearance rate (MCR),"DHEA is cleared rapidly from the blood, with a metabolic clearance rate (MCR) in the range of 2000 I/day, but the clearance of DHEAS is much slower and its MCR is in the range of 131/day.",Dehydroepiandrosterone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943796/),[i] / [d],2000,245145,DB01708,Dehydroepiandrosterone
,8943796,MCR,"DHEA is cleared rapidly from the blood, with a metabolic clearance rate (MCR) in the range of 2000 I/day, but the clearance of DHEAS is much slower and its MCR is in the range of 131/day.",Dehydroepiandrosterone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943796/),1/[d],131,245146,DB01708,Dehydroepiandrosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h],799,252501,DB01708,Dehydroepiandrosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h·m·sq],470,252502,DB01708,Dehydroepiandrosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h],751,252503,DB01708,Dehydroepiandrosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h·m·sq],444,252504,DB01708,Dehydroepiandrosterone
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260312,DB01708,Dehydroepiandrosterone
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260313,DB01708,Dehydroepiandrosterone
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260314,DB01708,Dehydroepiandrosterone
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260315,DB01708,Dehydroepiandrosterone
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],115,260316,DB01708,Dehydroepiandrosterone
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],183,260317,DB01708,Dehydroepiandrosterone
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,22,260318,DB01708,Dehydroepiandrosterone
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,25,260319,DB01708,Dehydroepiandrosterone
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,65,260320,DB01708,Dehydroepiandrosterone
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,57,260321,DB01708,Dehydroepiandrosterone
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,108,260322,DB01708,Dehydroepiandrosterone
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,129,260323,DB01708,Dehydroepiandrosterone
,25117615,tmax,"Over the evaluated dose range, plasma abiraterone concentrations increased with dose, with median tmax 2-3 h.",Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117615/),h,2-3,262377,DB01708,Dehydroepiandrosterone
,1833301,half-times,The half-life of DHAS was also calculated on two subjects; two main components of decay were detected with half-times of 0.73-1.08 and 23.1-28.8 h.,"Gonadotropin, prolactin and thyrotropin pituitary secretion after exogenous dehydroepiandrosterone-sulfate administration in normal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1833301/),h,0.73-1.08,266828,DB01708,Dehydroepiandrosterone
,1833301,half-times,The half-life of DHAS was also calculated on two subjects; two main components of decay were detected with half-times of 0.73-1.08 and 23.1-28.8 h.,"Gonadotropin, prolactin and thyrotropin pituitary secretion after exogenous dehydroepiandrosterone-sulfate administration in normal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1833301/),h,23.1-28.8,266829,DB01708,Dehydroepiandrosterone
